Executive Summary
Nine mega contracts totaling $2.5B signal robust federal demand for IT services, disaster recovery construction, and biothreat biotech R&D, providing multi-year revenue visibility to 2031 for recipients like Booz Allen Hamilton and Textron. All bullish awards via full/open competition highlight steady execution with $2.5B obligated (avg $283M/contract), though firm-fixed-price structures dominate 6/9 deals risking cost overruns. Investors should prioritize public parents (BAH, TXT) and monitor HHS/BARDA cluster (37% of value) for health security trends amid low initial outlays in 5/9 contracts.
Tracking the trend? Catch up on the prior Mega Contracts Monitor ($100M+) digest from February 19, 2026.
Investment Signals(3)
- Federal IT Services Revenue Ramp(HIGH)▲
GSA/DHS awards to Booz Allen ($746M), Peraton ($211M), Tatitlek ($116M) total $1.1B obligated, with options up to $1.7B through 2028, signaling sustained demand for NAICS 541512/541330.
- Biothreat Biotech R&D Commitment(HIGH)▲
HHS/BARDA contracts to Paratek ($265M), Luminary Labs ($100M) total $365M through 2029, with $139M outlayed, underscoring long-term funding for NAICS 541714 antibiotics/R&D.
- Infrastructure/Defense Construction Surge(MEDIUM)▲
DoD/USDA awards to Clark ($616M hospital), Kiewit ($242M Helene recovery) total $858M firm-fixed-price through 2028, matching base+options with zero outlays signaling front-loaded commitments.
Risk Flags(2)
- Execution[HIGH RISK]▼
Firm-fixed-price in 6/9 contracts ($2B value) exposes to cost overruns/inflation over long periods (avg 5+ years); low outlays ($0 in 3/9) indicate delays.
- Market[MEDIUM RISK]▼
Heavy subawards (e.g., Peraton $258M/53 subs, Kiewit $35M/5) and dependency on options (~$900M unexercised across portfolio) risk non-realization.
Opportunities(3)
- ◆
$900M+ in unexercised options (e.g., Peraton $142M, Booz $432M) across IT/biotech deals through 2028.
- ◆
HHS/BARDA biotech focus (3/9 contracts, $482M potential) amid biothreat priorities; disaster recovery (Kiewit) signals infra follow-ons.
- ◆
Public exposure via BAH ($746M GSA IT) and TXT ($134M FAA aircraft through 2031) undervalued on long visibility.
Sector Themes(3)
- ◆
4/9 contracts ($1.2B, 47% value) in NAICS 541512/541330 for GSA/DHS/DoD, with cost-plus and T&M structures.
- ◆
HHS/BARDA awards (3/9, $481M potential through 2029) emphasize biotech for biothreats via firm-fixed-price.
- ◆
Construction deals ($858M) for VA hospital and Helene recovery under DoD/USDA through 2028.
Watch List(3)
- 👁
{"entity"=>"Booz Allen Hamilton Holding Corp (BAH)", "reason"=>"Largest single award ($746M GSA IT transfer) with $432M options; ends 2024 needing follow-on.", "trigger"=>"New GSA task orders or Q2 backlog report"}
- 👁
{"entity"=>"Textron Inc (TXT)", "reason"=>"FAA aircraft order ($134M obligated, $283M potential) through 2031 signals aviation backlog.", "trigger"=>"Additional task order funding >$50M"}
- 👁
{"entity"=>"HHS/BARDA Biotech Cluster", "reason"=>"37% value in biothreat R&D (Paratek/Luminary); low outlays risk but long 5-10yr tails.", "trigger"=>"Outlays >50% of obligation or new awards"}
Get daily alerts with 3 investment signals, 2 risk alerts, 3 opportunities and full AI analysis of all 9 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC